{
  "stage": "S3",
  "passed": false,
  "convergence_score": 0.9215,
  "convergence_threshold": 0.85,
  "convergence_pass": true,
  "jaccard": 0.5529,
  "jaccard_threshold": 0.85,
  "jaccard_pass": false,
  "type_01_ratio": 0.6316,
  "type_01_threshold": 0.75,
  "type_pass": false,
  "cosine": 0.9215,
  "jsd": 0.2502,
  "kappa": 0.9471,
  "type_distribution": {
    "0": 0.47368421052631576,
    "1": 0.15789473684210525,
    "2": 0.10526315789473684,
    "3": 0.2631578947368421
  },
  "divergence_map": {
    "total_unique_claims": 19,
    "most_divergent": [
      {
        "statement": "1:** HK-II displacement is necessary but insufficient for cytochrome c release; the commitment point is VDAC1 oligomerization into a cytochrome c\u2013permeable supercomplex, which requires concurrent loss of Bcl-xL restraint AND permissive lipid environment (cardiolipin exposure).",
        "models_supporting": [
          "claude"
        ],
        "types_assigned": [
          2
        ],
        "confidences": [
          0.72
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "2:** The Warburg phenotype creates a biphasic dose-response with a sharp inflection, not a gradual curve. At [CBD] < Kd (< 11 \u00b5M), VDAC1 occupancy by HK-II remains >90% due to affinity mismatch (HK-II Kd ~nM vs CBD Kd = 11 \u00b5M), and cytoprotective targets (TRPV1 Kd=2 \u00b5M, PPAR\u03b3 EC50=5 \u00b5M) dominate. Above ~15\u201320 \u00b5M, cooperative displacement occurs because HK-II binding is stabilized by G6P product; once metabolic flux is disrupted, HK-II affinity drops, creating a positive-feedback collapse.",
        "models_supporting": [
          "claude"
        ],
        "types_assigned": [
          2
        ],
        "confidences": [
          0.68
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "3:** 2-DG + ABT-737 synergy is supra-additive because they collapse two independent stabilizing clamps simultaneously, lowering the effective CBD concentration needed for apoptosis from ~20 \u00b5M to within the therapeutic window (1\u201310 \u00b5M).",
        "models_supporting": [
          "claude"
        ],
        "types_assigned": [
          2
        ],
        "confidences": [
          0.65
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "4:** Cardiolipin enrichment at the OMM lowers the apoptotic threshold by ~2-fold by stabilizing VDAC1 oligomers and facilitating Bax insertion, while cholesterol opposes this by rigidifying the membrane and stabilizing monomeric VDAC1.",
        "models_supporting": [
          "claude"
        ],
        "types_assigned": [
          3
        ],
        "confidences": [
          0.45
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "1:** HK-II displacement by CBD/erastin is the *primary* death signal, with cytochrome c release driven by CL peroxidation (via Bax recruitment) rather than direct VDAC1 conductance changes.",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.85
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "2:** The Warburg phenotype (high HK-II-VDAC1 coupling) creates a biphasic CBD response: cytoprotection at low doses (<5 \u00b5M) via TRPV1/PPAR\u03b3 survival signaling, and apoptosis at high doses (>15 \u00b5M) via HK-II displacement and anti-apoptotic reserve saturation.",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.8
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "3:** 2-DG + ABT-737 synergistically shift the VDAC1 decision gate toward apoptosis by simultaneously removing HK-II (metabolic clamp) and Bcl-xL (signaling clamp), lowering the apoptotic threshold [CBD] by \u22653-fold.",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.75
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "4:** Cardiolipin (CL) enrichment in the OMM lowers the apoptotic threshold for CBD by ~2\u20133-fold (EC50 shift from ~20 \u00b5M to ~8 \u00b5M) by promoting VDAC1 oligomerization and Bax insertion, while cholesterol elevation raises it equivalently.",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          2
        ],
        "confidences": [
          0.5
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "HK-II displacement by CBD/erastin is the primary cyt c release trigger via CL unmasking/peroxidation, secondary to VDAC conductance change; tubulin blockade acts redundantly but weaker.",
        "models_supporting": [
          "grok"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.82
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "Warburg high HK-II-VDAC occupancy (>80%) protects vs low CBD (1-5 \u00b5M, <50% displacement) via glycolytic ATP + TRPV1/PPAR\u03b3 cytoprotection (EC50 2-5 \u00b5M), but sensitizes at high (15+ \u00b5M) by saturating HK-II buffer (mass-action >Kd=11 \u00b5M).",
        "models_supporting": [
          "grok"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.79
        ],
        "type_variance": 0,
        "n_supporters": 1
      }
    ],
    "models_present": [
      "claude",
      "mistral",
      "grok",
      "gemini",
      "deepseek"
    ]
  },
  "recommendation": "S3 gate FAILED. The system did not converge to stable consensus. This indicates genuine scientific disagreement worth investigating. Review the divergence map below."
}